Cite
Impact of hepatitis B core‐related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.
MLA
Hosaka, Tetsuya, et al. “Impact of Hepatitis B Core‐related Antigen on the Incidence of Hepatocellular Carcinoma in Patients Treated with Nucleos(t)Ide Analogues.” Alimentary Pharmacology & Therapeutics, vol. 49, no. 4, Feb. 2019, pp. 457–71. EBSCOhost, https://doi.org/10.1111/apt.15108.
APA
Hosaka, T., Suzuki, F., Kobayashi, M., Fujiyama, S., Kawamura, Y., Sezaki, H., Akuta, N., Suzuki, Y., Saitoh, S., Arase, Y., Ikeda, K., Kobayashi, M., & Kumada, H. (2019). Impact of hepatitis B core‐related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Alimentary Pharmacology & Therapeutics, 49(4), 457–471. https://doi.org/10.1111/apt.15108
Chicago
Hosaka, Tetsuya, Fumitaka Suzuki, Masahiro Kobayashi, Shunichirou Fujiyama, Yusuke Kawamura, Hitomi Sezaki, Norio Akuta, et al. 2019. “Impact of Hepatitis B Core‐related Antigen on the Incidence of Hepatocellular Carcinoma in Patients Treated with Nucleos(t)Ide Analogues.” Alimentary Pharmacology & Therapeutics 49 (4): 457–71. doi:10.1111/apt.15108.